ZymoGenetics lines up $100M

ZymoGenetics has lined up $100 million in fresh financing from Deerfield Management. ZymoGenetics can tap that money in $25 million allotments anytime over the next 18 months. And each tranche will reward Deerfield in a two percent royalty stream from the biotech's Recothrom, a blood-clotting drug. Deerfield will also receive 1.5 million warrants priced at $10.34 on the first draw and a million warrants on each subsequent draw priced at 25 percent above the 15-day average share price. Release

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.